Table 2 Baseline characteristics
N (%) | CR (n=62) | TT (n=59) |
|---|---|---|
Age | ||
 Mean age at randomization (SD) | 58 (11) | 55 (11) |
 >/=65 years old | 21 (34) | 13 (22) |
 > 65 years old | 41 (66) | 46 (78) |
Surgery | ||
 Mastectomy | 19 (31) | 26 (31) |
 Segmentectomy | 43 (69) | 33 (69) |
 Axillary nodes | 10 (16) | 16 (27) |
 Sentinel nodes | 43 (69) | 30 (51) |
 Sentinel & axillary nodes | 9 (15) | 13 (22) |
Tumor grade & nodal status | ||
 T1 | 38 (61) | 39 (66) |
 T2 | 24 (39) | 20 (34) |
 N0 | 46 (74) | 38 (64) |
 N1, LNR 0.01-0.20 | 11 (69) | 18 (86) |
 N1, LNR 0.21-0.65 | 5 (31) | 3 (14) |
 N1, LNR >0.65 | 0 | 0 |
Side | ||
 Right | 30 (48) | 24 (41) |
 Left | 32 (52) | 35 (59) |
Mean size of largest tumor (mm) (SD) | ||
 T1 (<=20 mm) | 12,5 (4,8) | 13,4 (4,9) |
 T2 (21–50 mm) | 25,4 (6,9) | 27,5 (5,9) |
Quadrant | ||
 Central | 6 (10) | 9 (15) |
 Supero-interne | 12 (19) | 10 (17) |
 Infero-interne | 9 (15) | 1 (2) |
 Supero-externe | 21 (33) | 32 (54) |
 Infero-externe | 6 (10) | 4 (7) |
 Overlapping | 5 (8) | 2 (3) |
 >/= 2 locations | 3 (5) | 1 (2) |
Histology grade | ||
 1 | 17 (27) | 16 (27) |
 2 | 25 (40) | 29 (49) |
 3 | 16 (26) | 12 (20) |
 Unknown | 4 (7) | 2 (4) |
Estrogen positive | 54 (87) | 48 (81) |
Progesterone positive | 45 (73) | 46 (78) |
Her2 FISH positive | 3 (5) | 10 (17) |
Adjuvant radio-chemotherapy (RT-CT) schedule | ||
 No CT | 37 (60) | 29 (49) |
 RT concurrent with CT | 19 (30) | 23 (39) |
 RT after CT (sequential)* (one patient neo-adj CT) | 6 (10) | 7 (12)* |
Chemotherapy type | ||
 Anthracycline without taxane | 4 (16) | 5 (17) |
 Anthracycline with taxane | 16 (64) | 19 (63) |
 CMF | 2 (8) | 2 (7) |
 Anthracycline with taxotere | 1 (4) | 3 (10) |
 TCH | 2 (8) | 1 (3) |
Hormonal therapy (HT) | ||
 No HT | 9 (14) | 11 (19) |
 Tamoxifen | 26 (42) | 16 (28) |
 Femara | 24 (39) | 22 (38) |
 Zoladex | 0 | 2 (3) |
 Tamoxifen + zoladex | 3 (5) | 6 (10) |
 Femara + zoladex | 0 | 1 (2) |
Herceptin (Trastuzumab) | 3 (5) | 10 (17) |